EUVIMEDEUVIMED entdecken
Fallbericht

Use of thrombin time to transition from dabigatran to intravenous unfractionated heparin in patients with acute kidney injury

Donna Barakeh iD, Kevin R Donahue, Mahmoud Sabawi, Diane Dreucean

American Journal of Health-System Pharmacy · 2025

DOI: 10.1093/ajhp/zxaf059 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Health-System Pharmacy, 2025. Verfasst von Donna Barakeh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Houston Methodist Hospital, Houston, TX, USA. Hauptthemen laut MEDLINE: Dabigatran, Acute Kidney Injury, Heparin, Antithrombins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This case series explores the use of thrombin time (TT) to transition 2 patients from dabigatran to unfractionated heparin (UFH) in the setting of acute kidney injury (AKI) and coagulopathy concerning for dabigatran accumulation. Summary Serial TT monitoring was employed until the value began to trend below 120 seconds, indicating ongoing drug clearance, at which point UFH was initiated. Patient 1 experienced rectal bleeding following initiation of UFH, while patient 2 experienced hemoglobin drops without an apparent bleeding source. No thrombotic events occurred during either hospitalization.

Conclusion

Individualized management remains paramount to balance bleeding and thrombotic risk based on patient-specific factors. Further research is warranted to validate the safety and efficacy of a TT-guided transition strategy and optimize protocols for hospitalized patients transitioning from dabigatran to UFH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DabigatranAcute Kidney InjuryHeparinAntithrombinsAnticoagulantsHumansAgedMaleThrombin TimeFemaleMiddle AgedAged, 80 and overHemorrhage

Stichwörter der Autor:innen

coagulation assaydabigatrandirect thrombin inhibitorthrombin timetransition

Substanzen

DabigatranHeparinAntithrombinsAnticoagulants

Autor:innen und Institutionen

  • Department of Pharmacy, Houston Methodist Hospital, Houston, TX, USA.
  • Department of Pharmacy, Houston Methodist Willowbrook Hospital, Houston, TX, USA.

ORCID-Profile: Donna Barakeh

Zitieren

APA

Barakeh, D., Donahue, K. R., Sabawi, M., & Dreucean, D. (2025). Use of thrombin time to transition from dabigatran to intravenous unfractionated heparin in patients with acute kidney injury. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaf059

Vancouver

Barakeh D, Donahue KR, Sabawi M, Dreucean D. Use of thrombin time to transition from dabigatran to intravenous unfractionated heparin in patients with acute kidney injury. American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxaf059

BibTeX
@article{Barakeh2025,
  author = {Barakeh, Donna and Donahue, Kevin R and Sabawi, Mahmoud and Dreucean, Diane},
  title = {Use of thrombin time to transition from dabigatran to intravenous unfractionated heparin in patients with acute kidney injury},
  journal = {American Journal of Health-System Pharmacy},
  year = {2025},
  doi = {10.1093/ajhp/zxaf059}
}
Kostenlos starten →